198 related articles for article (PubMed ID: 33836300)
1. Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents.
Tan HL; Tang LWT; Chin SY; Chan ECY
Drug Metab Pharmacokinet; 2021 Jun; 38():100390. PubMed ID: 33836300
[TBL] [Abstract][Full Text] [Related]
2. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
Karkhanis A; Lam HY; Venkatesan G; Koh SK; Chai CL; Zhou L; Hong Y; Kojodjojo P; Chan EC
Biochem Pharmacol; 2016 May; 107():67-80. PubMed ID: 26972388
[TBL] [Abstract][Full Text] [Related]
3. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Cheong EJ; Goh JJ; Hong Y; Venkatesan G; Liu Y; Chiu GN; Kojodjojo P; Chan EC
Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
[TBL] [Abstract][Full Text] [Related]
4. Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids.
Karkhanis A; Tram NDT; Chan ECY
Biochem Pharmacol; 2017 Dec; 146():188-198. PubMed ID: 28958841
[TBL] [Abstract][Full Text] [Related]
5. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Leow JWH; Ang XJ; Chan ECY
Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
[TBL] [Abstract][Full Text] [Related]
6. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
Cheong EJY; Teo DWX; Chua DXY; Chan ECY
Drug Metab Dispos; 2019 Nov; 47(11):1291-1306. PubMed ID: 31506301
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat and its major acyl glucuronide metabolite are potent inhibitors of organic anion transporter 3: Implications for drug-drug interactions with rivaroxaban.
Tang LWT; Cheong TWH; Chan ECY
Biopharm Drug Dispos; 2022 Apr; 43(2):57-65. PubMed ID: 35088420
[TBL] [Abstract][Full Text] [Related]
8. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
Wen HN; He QF; Xiang XQ; Jiao Z; Yu JG
Thromb Res; 2022 Oct; 218():24-34. PubMed ID: 35985100
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation.
Dorian P
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):15S-8S. PubMed ID: 20472816
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of the rivaroxaban-dronedarone interaction: insights from physiologically based pharmacokinetic modelling.
Hügl B; Horlitz M; Fischer K; Kreutz R
Eur Heart J Open; 2023 Jan; 3(1):oead004. PubMed ID: 36820238
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Effects of Dronedarone on Small Conductance Calcium Activated Potassium Channels in Patients with Chronic Atrial Fibrillation: Comparison to Amiodarone.
Yu Y; Luo D; Li Z; Zhang J; Li F; Qiao J; Yu F; Li M
Med Sci Monit; 2020 May; 26():e924215. PubMed ID: 32470968
[TBL] [Abstract][Full Text] [Related]
12. Effect of antiarrhythmic drugs on small conductance calcium - activated potassium channels.
Simó-Vicens R; Sauter DRP; Grunnet M; Diness JG; Bentzen BH
Eur J Pharmacol; 2017 May; 803():118-123. PubMed ID: 28322838
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Chiou WR; Huang CC; Lin PL; Chuang JY; Liu LY; Su MI; Liao FC; Chen CY; Kuo JY; Tsai CT; Wu YJ; Lee YH
Am J Cardiovasc Drugs; 2021 Jul; 21(4):459-469. PubMed ID: 33369716
[TBL] [Abstract][Full Text] [Related]
14. Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs.
Marada VV; Flörl S; Kühne A; Müller J; Burckhardt G; Hagos Y
Pharmacol Res; 2015 Jan; 91():78-87. PubMed ID: 25481222
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of potential herb-drug interactions between oseltamivir and commonly used anti-influenza Chinese medicinal herbs.
Zhang Y; Lyu C; Fong SYK; Wang Q; Li C; Ho NJ; Chan KS; Yan X; Zuo Z
J Ethnopharmacol; 2019 Oct; 243():112097. PubMed ID: 31325600
[TBL] [Abstract][Full Text] [Related]
16. Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation.
Zhang P; Wang M; Liu W; Sun P; Cai S; Pan Y; Zhao Q
J Interv Card Electrophysiol; 2022 Jun; 64(1):121-127. PubMed ID: 35050451
[TBL] [Abstract][Full Text] [Related]
17. Dronedarone for atrial fibrillation therapy.
Marzocchi M; Lombardi F
Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):675-83. PubMed ID: 21714598
[TBL] [Abstract][Full Text] [Related]
18. Dronedarone--a new alternative for management of atrial fibrillation.
Hundal M; Garg RK
Recent Pat Cardiovasc Drug Discov; 2010 Jan; 5(1):47-53. PubMed ID: 20001929
[TBL] [Abstract][Full Text] [Related]
19. Dronedarone: a review of characteristics and clinical data.
Baroletti S; Catella J; Ehle M; Cheng JW
Crit Pathw Cardiol; 2010 Jun; 9(2):94-101. PubMed ID: 20520217
[TBL] [Abstract][Full Text] [Related]
20. Dronedarone for the management of atrial fibrillation.
Brenner R; Delacrétaz E
Swiss Med Wkly; 2011; 141():w13158. PubMed ID: 21370206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
